Riskpilot← Back to searchSign inGet full accessNew Cardiolab ApS
APSActiveCVR 36895705Thurøvej 24, st. tvMedical specialists activities · NACE 8622Est. 20157 employeeswww.cardiolab.dk
Revenue 2024
DKK 1,5M
+30% vs 2023
EBITDA margin
11.4%
+161% vs 2023
Equity ratio
8.3%
Financial strength
Net profit 2024
DKK 1,1M
+390% vs 2023
| Revenue | DKK 1,5M | +30% |
| EBITDA | DKK 169K | +161% |
| Net profit | DKK 1,1M | +390% |
| Total assets | DKK 2,7M | +137% |
| Equity | DKK 224K | +126% |
| Employees | 7 | — |
Legal name
New Cardiolab ApS
CVR number
36895705
Legal form
Anpartsselskab
NACE code
8622 · Medical specialists activities
Founded
18. maj 2015
Share capital
DKK 50.000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør eller af den samlede direktion.
Company purpose
Selskabets formål er at tilbyde forebyggende lægebehandlinger samt hermed beslægtet virksomhed.
Address
Thurøvej 24, st. tv
Phone
+4553540552
Email
janet@alsoe.dk
Website
www.cardiolab.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 61 | -279 | 157 | 172 | 240 | 80 | 195 | 1.192 | 1.140 | 1.484 |
| Staff expenses | -293 | -527 | -286 | -209 | -187 | -64 | -66 | -1.186 | -1.418 | -1.315 |
| EBITDA | -232 | -806 | -129 | -37 | 53 | 16 | 129 | 7 | -277 | 169 |
| Depreciation & amort. | -20 | -40 | -40 | -40 | -40 | -20 | -0 | -0 | -0 | -0 |
| EBIT | -252 | -846 | -169 | -77 | 13 | -4 | 129 | 7 | -277 | 169 |
| Net financials | -7 | -15 | -285 | -18 | 299 | -30 | 310 | 117 | -99 | 739 |
| Profit before tax | -259 | -862 | -454 | -94 | 312 | -34 | 438 | 124 | -376 | 908 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -78 | -56 | 3 | -191 |
| Net profit | -259 | -862 | -454 | -94 | 312 | -34 | 516 | 180 | -379 | 1.099 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 322 | 330 | 387 | 633 | 1.103 | 1.507 | 751 | 1.208 | 1.135 | 2.692 |
| Equity | -59 | -920 | -1.375 | -1.469 | -1.157 | -1.192 | -675 | -496 | -875 | 224 |
| Long-term debt | 304 | 1.181 | 1.604 | 1.982 | 2.019 | 2.488 | 1.165 | 1.074 | 1.760 | 1.700 |
| Short-term debt | 77 | 69 | 158 | 120 | 242 | 210 | 261 | 629 | 250 | 768 |
| Total debt | 381 | 1.251 | 1.762 | 2.102 | 2.260 | 2.698 | 1.426 | 1.703 | 2.010 | 2.468 |
EBITDA margin
11.4%
This company
15.8%
Market median
-28% vs market
20152024
Equity ratio
8.3%
This company
38.2%
Market median
-78% vs market
20152024
Return on equity
489.8%
This company
18.4%
Market median
+2562% vs market
20152024
Net profit margin
74.1%
This company
8.1%
Market median
+815% vs market
20152024
Asset turnover
0.55×
This company
1.12×
Market median
-51% vs market
20152024
Debt / equity
10.99×
This company
0.62×
Market median
-1673% vs market
20152024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-05-18 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SA Management | Management | 2023 | — | — |
JA Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Janet Alsø Holding ApS | Company | 50.0% | 50.0% | 2021 |
Susan Alsø Holding ApS | Company | 50.0% | 50.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Susan Alsø Holding ApS
New Cardiolab ApS Board members of New Cardiolab ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Susan Alsø | Management | 0 companies |
| Janet Alsø | Chief Executive Officer | 0 companies |